A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex
A Prospective, Multinational, Multicenter, Randomized, Sequential, Double-blind, Placebo-controlled, Phase 2a Clinical Trial to Assess the Safety and Pharmacokinetics of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex (ABC).
- Hospital-acquired Bacterial Pneumonia
- Ventilator-associated Bacterial Pneumonia
At a glance
- Phase
- Phase 2
- Study type
- Interventional
- Sponsor
- Omnix Medical Ltd
- Enrolment target
- 54
- Started
- 14 May 2026
- Main results due
- March 2027
- Study sites
- 15
- Registry updated
- 28 September 2026
Can you take part?
- Ages 18 years to 99 years.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: 1. A signed informed consent form. 2. Male or female patients 18 years or older 3. A diagnosis of either a HABP or a VABP 4. ABC infection of the lower respiratory tract suspected based on a positive rapid testing of respiratory specimens 5. Women of childbearing potential (WOCBP) (i.e., not post-menopausal or surgically sterilized) must have a negative highly sensitive urine or serum pregnancy test before randomization. 6. Acute Physiology and Chronic Health Evaluation II (APACHE II) score between 10 and 24 Exclusion Criteria: 1. Moderate to severe reduction of renal function 2. Liver dysfunction 3. Evidence of septic shock 4. Acute respiratory distress syndrome. 5. Immunosuppressed patients (due to either immunosuppressant drugs or to any medical condition). 6. History of any known hypersensitivity to colistin or to carbapenems 7. Any condition or circumstance that, in the opinion of the investigator, would compromise the safety of the patient or the quality of the study data
What this study is about
In the sponsor’s own words, from the registry.
This is a phase 2a, multinational, multicenter, double-blind, randomized, placebo-controlled, dose-ranging safety, tolerability and PK study in patients with HABP (Hospital Acquired Bacterial Pneumonia) or VABP (Ventilator Associated Bacterial Pneumonia) caused by ABC to identify safe and well-tolerated doses and to assess the PK profile of OMN6 in patients.
Study sites(15)
Omnix Medical Research Site 1
Athens, Greece
Recruiting
Omnix Medical Research Site 2
Athens, Greece
Recruiting
Omnix Medical Research Site 3
Athens, Greece
Recruiting
Omnix Medical Research Site 4
Athens, Greece
Recruiting
Omnix Medical Research Site
Ioannina, Greece
Recruiting
Omnix Medical Research Site 1
Thessaloniki, Greece
Recruiting
Omnix Medical Research Site 2
Thessaloniki, Greece
Recruiting
Omnix Medical Research Site 3
Thessaloniki, Greece
Recruiting
Omnix Medical Research Site 4
Thessaloniki, Greece
Recruiting
Omnix Medical Research Site
Ashdod, Israel
Recruiting
Omnix Medical Research Site
Be’er Ya‘aqov, Israel
Recruiting
Omnix Medical Research Site
Holon, Israel
Recruiting
Omnix Medical Research Site
Petah Tikva, Israel
Recruiting
Omnix Medical Research Site
Ramat Gan, Israel
Recruiting
Omnix Medical Research Site
Rishon LeZiyyon, Israel
Recruiting
Showing 15 of 15 sites. 15 of the 15 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT06087536. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me